Researchers have developed a lipid nanoparticle platform that physically changes size inside the body to slip past the pancreas’s protective outer layer, delivering mRNA cargo to pancreatic tissue after intraperitoneal injection into the abdominal cavity. The system, called AH-LNP, exploits a newly identified filtering mechanism of organ capsules to help drive selective accumulation in the pancreas while minimizing liver uptake, which has long dominated nanoparticle distribution. The work addresses one of the most stubborn problems in RNA medicine: getting therapeutic molecules to organs that standard delivery systems simply cannot reach.
In mouse studies, the AH-LNP particles were administered into the peritoneal space and then tracked as they interacted with proteins, reorganized, and ultimately penetrated the pancreatic capsule. According to the Lei et al. report, this dynamic behavior enabled mRNA expression in pancreatic cells while minimizing signal in the liver and other abdominal organs in mice. Because the approach relies on physical size transitions rather than a single receptor or cell type, the authors argue that the underlying principle could be generalized to other nanoparticle formulations designed for difficult-to-access tissues.
How Organ Capsules Act as Size Filters
Most lipid nanoparticles injected into the bloodstream end up trapped in the liver, a pattern driven by protein binding and receptor interactions that have frustrated efforts to treat diseases in other organs. Systemic mRNA delivery to tissues beyond the liver, spleen, and lungs has remained especially difficult, limiting the clinical reach of RNA-based therapies. The AH-LNP platform sidesteps this bottleneck entirely by using a different route: intraperitoneal injection, which places nanoparticles directly into the abdominal cavity rather than the bloodstream and brings them into close contact with organ surfaces.
The key insight, reported in the pancreas-targeting study, is that organ capsules, the thin membranes wrapping organs like the pancreas, act as physical filters. Large nanoparticles cannot pass through these dense collagenous barriers, but the AH-LNP system first assembles into bigger structures after interacting with proteins in the peritoneal fluid, then shifts to a smaller size that can penetrate the pancreatic capsule. The researchers call this the CAMP mechanism and propose that the filtering principle is broadly applicable across various delivery systems, not just their own formulation. That distinction matters because it suggests a general design rule other labs could adopt when engineering particles for capsule-enclosed organs.
Why the Liver Has Dominated RNA Delivery
The liver’s grip on nanoparticle uptake is not accidental. Earlier work on selective organ targeting, or SORT, nanoparticles showed that adding a supplemental lipid molecule could tune organ tropism toward the lung, spleen, or liver, but the pancreas remained out of reach through intravenous injection. Mechanistic studies of SORT formulations revealed that tissue specificity depends on PEG-lipid desorption, serum protein binding, and receptor interactions that overwhelmingly favor hepatocytes. Parenteral nanoparticles also show poor localization to the gastrointestinal tract, further narrowing the delivery window for abdominal organs that sit behind multiple anatomical barriers.
The AH-LNP approach breaks from this pattern by combining two strategies that a Nature News and Views commentary describes as a two-pronged method: size-based filtration through the organ capsule plus receptor-mediated uptake once particles reach pancreatic cells. Extrahepatic targeting has been a central limitation for clinical LNP RNA delivery, that commentary notes, making the physical bypass of liver accumulation a significant technical step. The distinction between tweaking lipid chemistry, as SORT does, and exploiting anatomical barriers, as AH-LNP does, represents a fundamentally different engineering philosophy for organ-selective delivery and may open a complementary design space for future formulations.
Earlier Attempts to Reach the Pancreas
The AH-LNP system did not emerge in a vacuum. A 2023 study demonstrated that ionizable lipid nanoparticles could deliver mRNA to pancreatic beta cells through macrophage-mediated transfer after intraperitoneal administration. In that work, peritoneal macrophages took up the nanoparticles and then shuttled mRNA to beta cells via extracellular vesicles, an indirect but functional route that nonetheless depended on immune-cell trafficking. Separately, researchers at Carnegie Mellon University reported mRNA delivery to pancreatic cells in mice after intraperitoneal dosing, illustrating that different formulations and delivery routes can bias expression toward distinct endocrine cell types.
A different team developed the ENDO platform, which contains cholecalciferol (vitamin D3) and uses the vitamin D receptor to route nanoparticles to the pancreas through systemic injection. In that strategy, the vitamin D motif serves as a molecular address that guides particles toward receptor-rich tissues, including pancreatic islets, after intravenous dosing. Each of these approaches found a path to pancreatic tissue, but none offered a clear, reproducible physical principle for selective delivery. The macrophage relay depends on biological intermediaries that are hard to control, while vitamin D receptor routing ties specificity to a single molecular target that may vary between patients or disease states. What sets the AH-LNP apart, at least in preclinical data, is that its size-shifting mechanism operates through a structural property of the organ itself rather than relying on any one receptor or immune cell behavior.
Cancer and Diabetes Applications
The diseases most likely to benefit from pancreas-targeted mRNA delivery are pancreatic cancer and type 1 diabetes. Pancreatic ductal adenocarcinoma accounts for around 90% of pancreatic malignancies and shows limited response to immune therapy, making it one of the deadliest solid tumors. A preclinical study using pancreas-targeted LNPs loaded with IL-12 mRNA reported tumor eradication in some orthotopic PDAC models and demonstrated immune-cell engagement within the tumor microenvironment, all via intraperitoneal delivery. If the AH-LNP platform can similarly concentrate potent immunostimulatory payloads in and around pancreatic tumors while minimizing liver exposure, it could potentially support combination approaches that are harder to pursue when systemic exposure is high.
For type 1 diabetes, direct delivery of mRNA to islet cells could support several therapeutic concepts, from transient expression of insulin or protective cytokines to in situ reprogramming of non-beta cells into insulin producers. Earlier alpha-cell targeting work hinted that nanoparticle-mediated reprogramming is feasible in principle, and the ENDO and macrophage-based platforms have already shown that pancreatic endocrine cells can be genetically manipulated in vivo. AH-LNPs add a new option: exploiting capsule permeability to reach the organ as a whole and then relying on cell-type–specific promoters or ligands to refine which populations express the encoded protein. Before any of these ideas move toward the clinic, however, researchers will need to establish long-term safety, repeat-dosing tolerability, and the risk of off-target expression in other capsule-bearing organs.
What Comes Next for Size-Gated Delivery
The discovery that organ capsules can act as tunable size filters suggests a broader framework for extrahepatic mRNA delivery. If capsule thickness and pore architecture vary between organs, disease states, or even individuals, then nanoparticle engineers may be able to design formulations with programmable assembly and disassembly profiles that selectively access specific tissues after peritoneal or local administration. The CAMP mechanism described for AH-LNPs offers one blueprint: allow particles to form large aggregates that preferentially adhere to the target organ surface, then trigger a controlled transition to smaller units that slip through the capsule without diffusing widely elsewhere.
Translating that blueprint into human therapies will require careful mapping of capsule properties across species, as well as detailed pharmacokinetic and toxicology studies that have not yet been completed for AH-LNPs. The liver’s dominance in current clinical LNP pipelines reflects decades of optimization and a relatively forgiving safety profile for transient hepatic gene expression; shifting the focus to the pancreas introduces new concerns about inflammation, pancreatitis, and unintended effects on digestive or endocrine function. Even so, the convergence of macrophage-mediated delivery, receptor-guided platforms like ENDO, and size-gated systems such as AH-LNP underscores a rapid broadening of the RNA delivery toolkit. Instead of accepting the liver as the default destination, researchers are beginning to treat anatomical barriers as designable features, turning what once were obstacles into guides for where therapeutic mRNA ultimately goes.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
